What is the intrinsic value of LGND?
As of 2025-12-15, the Intrinsic Value of Ligand Pharmaceuticals Inc (LGND) is
61.71 USD. This LGND valuation is based on the model Peter Lynch Fair Value.
With the current market price of 189.55 USD, the upside of Ligand Pharmaceuticals Inc is
-67.44%.
Is LGND undervalued or overvalued?
Based on its market price of 189.55 USD and our intrinsic valuation, Ligand Pharmaceuticals Inc (LGND) is overvalued by 67.44%.
61.71 USD
Intrinsic Value
LGND Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(580.91) - (127.58) |
(198.88) |
-204.9% |
| DCF (Growth 10y) |
(175.63) - (797.55) |
(273.92) |
-244.5% |
| DCF (EBITDA 5y) |
(80.20) - (90.25) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(118.25) - (141.98) |
(1,234.50) |
-123450.0% |
| Fair Value |
61.71 - 61.71 |
61.71 |
-67.44% |
| P/E |
3.87 - 70.11 |
34.74 |
-81.7% |
| EV/EBITDA |
26.12 - 117.43 |
60.26 |
-68.2% |
| EPV |
17.99 - 31.22 |
24.61 |
-87.0% |
| DDM - Stable |
32.21 - 222.03 |
127.12 |
-32.9% |
| DDM - Multi |
4.16 - 22.32 |
7.01 |
-96.3% |
LGND Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
3,730.34 |
| Beta |
0.83 |
| Outstanding shares (mil) |
19.68 |
| Enterprise Value (mil) |
4,036.46 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.18% |
| Cost of Debt |
472.06% |
| WACC |
7.18% |